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The pharmaceutical industry, the medical device indus-
try, and national regulatory agencies such as the United
States Food and Drug Administration (FDA) are faced
with a number of difficult issues related to the develop-
ment and evaluation of health-related quality of life
(HRQL) claims for product labeling and promotion.
This paper outlines some of the unique challenges of
HRQL research and makes recommendations for assur-
ing that claims are based on the results of rigorous stud-
ies designed and conducted according to accepted scien-
tific principles and practices. Standards of evidence for
HRQL are discussed in terms of research design and
methodology, instrumentation, statistical analysis, and
interpretation. Examples are provided to highlight im-
portant points. The paper concludes with a brief discus-
sion of future trends in HRQL outcomes evaluation.
 
Introduction
 
The pharmaceutical industry, the medical device
industry, and national regulatory agencies such as
the United States (US) Food and Drug Administra-
tion (FDA), are faced with a number of difficult is-
sues related to the development and evaluation of
health-related quality of life (HRQL) claims for
product labeling and promotion. Many of these is-
sues emanate from three characteristics that are
inherent to HRQL evaluation and research, which,
in large part, are new to the field of medical re-
search. First, HRQL is a multidimensional, un-
observed construct that can be operationalized in
different ways, depending on the disease or treat-
ment. As a result, there is no single HRQL mea-
sure suitable for all clinical trials, and it is likely
that there are several appropriate instruments for
any given trial. Second, because HRQL relies on
the patient’s perception of functioning and well-
being, it is inherently and appropriately subjective.
Finally, there are unique challenges associated
with the statistical analysis of HRQL data, includ-
ing the handling of missing data cross-sectionally
and over time, and the simultaneous analysis of
multiple endpoints to avoid bias of various forms.
This paper reviews some of the challenges of
HRQL research and offers recommendations for
assuring that quality of life claims for labeling and
promotion are based on the results of rigorous
studies designed and conducted according to ac-
cepted principles and practices of the HRQL sci-
entific community.
 
Rationale
 
Medical treatment, and healthcare in general, is
aimed at improving survival and/or maintaining
or enhancing the patient’s quality of life. The clin-
ical, biochemical, and physiological benefits and
adverse effects of treatment can have a positive or
a negative impact on HRQL, making this an im-
portant outcome of treatment. The evaluation of
HRQL is taking on greater significance in the de-
velopment and evaluation of new pharmaceutical
agents and devices for several reasons [1]:
1. Evaluating HRQL helps translate clinical im-
provement into patient-centered outcomes. A
statistically significant improvement in pulmo-
nary function in patients with chronic airways
obstruction, for example, may or may not be
accompanied by improvements in activities of
daily living or feelings of well-being, which are
key dimensions of HRQL. Demonstrating im-
provement in both clinical and patient-centered
outcomes offers important information to con-
sumers regarding the value of treatment.
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2. HRQL is the outcome of choice for conditions
in which there are no physical, physiological,
or biochemical markers of disease activity, or
for situations in which treatment effectiveness
is based primarily on patient perception. Pain-
related conditions such as rheumatoid disor-
ders and gastroesophageal reflux disease, for
example, can have a profound adverse impact
on HRQL, effects that can improve dramati-
cally with treatment. Effectiveness of late-stage
cancers for which there is no known life-pro-
longing treatment is also based largely on
HRQL outcomes, rather than survival or other
clinical endpoints.
3. New treatments are available with efficacies
equivalent to standard treatments but with
fewer side effects and less adverse impact on
HRQL. Patients with hypertension, for exam-
ple, can achieve control over their blood pres-
sure while maintaining their HRQL, because of
improvements in the side effect profiles of anti-
hypertensive agents. Demonstrating stability
in HRQL or product superiority in this regard
helps clinicians and patients make informed de-
cisions as they consider treatment alternatives.
4. New treatments can involve a trade-off be-
tween efficacy and side effects. A new cancer
agent, for example, may offer improved effi-
cacy with more treatment-related toxicity. Un-
derstanding the impact of the intensity and du-
ration of side effects on HRQL can provide
insight into the nature of this trade-off and the
factors patients and providers consider in mak-
ing treatment decisions.
5. Rising healthcare costs have stimulated great
interest and debate about the cost-effective-
ness of new treatments, with HRQL quality-
adjusted life-years (QALYs) a key concern.
HRQL outcomes can be used in economic eval-
uations to assess the value of new treatment rel-
ative to the expenditures through cost-utility
analyses.
6. Finally, HRQL information can be useful for
promotional purposes by industry and formu-
lary listings by providers. In 1997 in the United
States, for example, the FDA agreed that Glaxo
Wellcome Inc. had sufficient empirical evi-
dence to support an asthma-specific quality of
life promotional claim for salmeterol xinafoate
(Serevent, Glaxo Wellcome Inc., Research Tri-
angle Park, NC). Under the agreement, Glaxo
Wellcome can provide patient outcome infor-
mation regarding asthma management with
salmeterol and educate the healthcare commu-
nity about disease-specific quality of life [2].
 
Definitions
 
The term “quality of life” is defined as the subjec-
tive perception of satisfaction or happiness with
life in domains of importance to the individual [3].
Because many factors other than health (e.g., eco-
nomic resources, housing, neighborhood safety,
and political conditions) can affect quality of life,
outcomes of disease and treatment generally are
evaluated under the more restricted concept and
term “health-related quality of life” (HRQL).
HRQL is defined as the subjective perception of
the impact of health status, including disease and
treatment, on physical, psychological, and social
functioning and well-being.
HRQL is a multidimensional construct that in-
cludes 
 
at least
 
 three core domains: physical, psy-
chological, and social, all of which must be ap-
praised in an HRQL evaluation [4]. These domains
may include, but are not limited to, an evaluation
of the effects of disease and/or treatment on physi-
cal or psychological symptoms, physical function,
social function, and emotional well-being. Other
dimensions of HRQL that may be evaluated in-
clude role function, cognitive function, sleep prob-
lems, sexuality and sexual function, vitality/energy,
pain, life satisfaction, body image, and general
perceptions of health.
In order for an HRQL evaluation to be valid,
the three core domains must be represented. Eval-
uating outcomes along one domain does not con-
stitute an HRQL assessment, and claims for label-
ing and/or promotion cannot be made. This
position is important for two reasons. First, be-
cause HRQL is a multidimensional construct,
evaluation of one domain alone violates the entire
premise of the construct. Second, it is possible that
a treatment may have a positive impact on one do-
main of HRQL and a negative impact on another.
For example, an agent or product may improve or
stabilize physical function but have an adverse im-
pact on psychological well-being or social func-
tioning. Similarly, a treatment may ameliorate or
eliminate symptoms, but have no impact on physi-
cal function, psychological well-being, or social
interaction. Unless each domain is represented, the
“true” HRQL effect is unknown. It is possible and
reasonable to expect that certain treatments
would yield a change in only one domain of
HRQL. In this case, an investigator(s) may elect to
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evaluate the single domain in isolation, under-
standing that the conclusions drawn, including
those for labeling or promotional purposes, reflect
this domain or construct only, and not HRQL.
 
Recommendations for Designing and 
Evaluating Clinical Trials for Quality
of Life Claims
 
The remainder of this document provides recom-
mendations for gathering and evaluating empirical
evidence to substantiate labeling or promotion
claims for the HRQL effects of pharmaceutical
agents or devices. The recommended standards of
evidence for HRQL are discussed in terms of (1)
research design and methodology; (2) measure-
ment; (3) statistical analysis; (4) interpretation.
Examples are provided to highlight important
points. The paper concludes with a brief overview
of future trends in HRQL outcomes evaluation.
 
Research Design and Methodology
 
Similar to the rigors of safety and efficacy studies,
documenting the impact of treatment on HRQL
outcomes requires evidence derived from carefully
designed and implemented randomized controlled
clinical trials [5]. Random allocation to treatment
group, fair and reasonable treatment comparators,
and complete follow-up are standard elements of a
sound trial and represent necessary conditions in
the evaluation of HRQL endpoints. Whether the
endpoint is considered primary or secondary, the
scientific principals of clinical trial design apply.
The research protocol should discuss the objec-
tives and methods in sufficient detail to permit a
thorough review and critique before data collec-
tion is begun. The methods section should include
the sample size and eligibility requirements that
are driven by this component of the trial (e.g., lan-
guage or reading requirements) and a complete de-
scription of the instrument(s) to be used (recom-
mendations regarding reliability and validity of
measures are provided in the following section).
Three elements of trial design are particularly im-
portant in conducting HRQL outcome studies and
should be addressed in the protocol: (1) adequate
assessment intervals; (2) appropriate procedures
for minimizing assessment bias; (3) a demonstra-
ble program for assuring data quality through
standardized training of study personnel.
 
Assessment Intervals.
 
The observation period for
HRQL data collection must correspond to the clin-
ical outcomes and consider both short- and long-
term effects of treatment on HRQL. Baseline, or
pretreatment, assessments of HRQL are critically
important and more than a single follow-up as-
sessment may be necessary [6]. Evaluations should
be of sufficient frequency to capture key effects,
including those related to the amelioration of dis-
ease and side effects or adverse events. For exam-
ple, in evaluating the impact of antihypertensives
on HRQL, it is important to gather data early in
the trial in order to capture the impact of adverse
events before dropout occurs. Assessments of
HRQL during long-term follow-up and open-label
studies (e.g., 4–12 months) are strongly advised,
since hypertensive patients will be asked to con-
tinue treatment for long periods of time. In clinical
trials of antineoplastic agents, HRQL may be as-
sessed only during the course of treatment, or may
include follow-up assessments to the first evidence
of disease progression. Evaluating the impact of
treatment for more episodic diseases, such as mi-
graine, can require different data collection proce-
dures or intervals (e.g., daily or weekly diary) in
order for HRQL to be adequately captured. The
research protocol should specify the frequency
and the time window for the collection of HRQL
data and the rationale for these decisions.
 
Minimizing Assessment Bias.
 
Appropriate proce-
dures for minimizing assessment bias must be built
into the research design and protocol. Although
this is true of any clinical trial, the fact that HRQL
evaluation is generally based solely on the pa-
tient’s perspective requires that even more care be
taken to prevent or minimize bias. HRQL instru-
ments can be administered through self-comple-
tion either with paper and pencil forms or com-
puter-administration, or through in-person or
telephone interviews.
The best time to complete questionnaires or in-
terviews during clinic visits is immediately after
the patient has arrived, before there are substan-
tial professional encounters with transmission of
information, such as disease status. Such informa-
tion may influence the answers that patients pro-
vide on questionnaires. Similarly, if telephone or
direct interviews are being used, they should be set
up at times that are not likely to be influenced by
immediately preceding events.
For self-completed HRQL assessments, standard-
ized procedures must be established to ensure that
the patient completes the forms independently. In-
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terview-administered questionnaires require struc-
tured scripts and careful monitoring to ensure
consistency in administration across patients, in-
terviewers, and sites and to minimize verbal and
nonverbal sources of bias. Centralized telephone in-
terviews can reduce investigator burden and mini-
mize bias through the use of standardized proto-
cols by interviewers blind to treatment. Regardless
of the method, reasonably detailed trial-specific
instructions regarding procedures for data collec-
tion, tracking of missing data, and the trans-
mission of data to the appropriate offices must be
included in the protocol. Full disclosure of incom-
plete data may include initialed notations of missed
items within a questionnaire, or a “face sheet” ap-
pended to the front of a questionnaire or interview
guide explaining why the data were not gathered
together with the signature of the responsible staff
member [7].
 
Standardized Training of Study Personnel.
 
Care-
ful training of data collection personnel, at the
clinical site or survey research center, is essential
to ensuring data quality through the standardized
administration of the HRQL measures. Clinical
study monitors should be trained to evaluate the
quality of the data collected and to keep sites ap-
prised of potential problems and how they should
be handled throughout the duration of the trial. A
detailed manual describing the instruments and
data collection procedures is needed for reference
by study center personnel. This manual should in-
clude guidelines for handling issues that can arise
with HRQL assessments, including questions pa-
tients commonly ask about items or question-
naires and what to do if a patient refuses to com-
plete certain items. Long-term studies and/or those
anticipating high rates of staff turnover should in-
clude plans for ongoing training and follow-up [8].
 
Measurement
 
Approaches.
 
There are a number of approaches
to evaluating HRQL. Generally, these are classi-
fied as global, generic, condition- or situation-spe-
cific, battery, and utility or preference. Although a
global approach can be used in clinical trials and
can provide important information concerning the
effect of disease and/or treatment on overall HRQL,
this approach lacks the comprehensiveness nec-
essary for substantiating HRQL claims. Generic,
condition- or situation-specific, battery, and util-
ity or preference measures should evaluate HRQL
from a multidimensional (physical, psychological,
and social) perspective, consistent with the current
consensus on the definition of HRQL and permit-
ting a full evaluation of the domains most affected
by disease and treatment. As noted below, these
approaches are not necessarily mutually exclusive,
and each approach or combination thereof should
be considered viable for gathering data for HRQL
claims.
The generic approach involves instruments with
broad applicability, permitting comparison of
HRQL profiles across patients with different dis-
eases (e.g., arthritis and hypertension). It also al-
lows for the evaluation of the relative efficacy of
treatments across different patient populations.
Because generic measures are less specific to the
unique difficulties associated with a given disease
or treatment, they can be less sensitive to treat-
ment effects [9]. The Medical Outcomes Study
Short Form 36 (SF-36) [10], Sickness Impact Pro-
file [11], and the Nottingham Health Profile [12]
are examples of generic HRQL measures.
The condition-specific approach (also referred
to as disease- or situation-specific) targets distinc-
tive HRQL effects associated with a specific dis-
ease (e.g., arthritis, asthma, HIV disease), family
of diseases (e.g., cancer), or situations. The latter
case can include settings, such as the intensive care
or nursing home, or therapies, such as radiation,
chemotherapy, or implantable devices. Although
the specificity of condition-specific instruments
can increase their sensitivity, it also eliminates the
possibility of comparing HRQL profiles or out-
comes across diagnostic groups.
The battery approach involves the use of multi-
ple instruments or modules to evaluate HRQL.
For example, multiple domain-specific instru-
ments may be used to assess psychological state,
physical functioning, and social functioning; a ge-
neric health status measure may be used together
with one or more condition-specific instruments;
generic or condition-specific measures may be
supplemented by one or more domain-specific
scales (e.g., pain, body image, or sexual function-
ing). Many oncology investigators now agree that
condition-specific measures should assess aspects
of HRQL common across various types of cancer
and include modules [13] or checklists [14] to
evaluate the unique experiences associated with
specific forms of cancer (e.g., prostrate, breast) or
treatment (e.g., chemotherapy, radiation). A bat-
tery is a fluid instrument; its constituent parts
change with the research question, leading to opti-
mal sensitivity in any given situation. The disad-
vantage of this approach can be the lack of consis-
tency across studies and, in the case of clinical
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trials, the inability to compare HRQL outcomes
across various treatment regimens or subpopula-
tions. By their nature, HRQL battery scores can-
not be aggregated into a composite score and must
therefore be presented as a profile. To be consid-
ered an HRQL measure, the battery must assess 
 
at
least
 
 the three core domains [4].
Another approach to HRQL evaluation is util-
ity- or preference-based. This is a rather unique
approach in that its explicit intent is to derive a
single value to represent the quality of life associ-
ated with a given health state. This value always
lies between 0 and 1 (or 0 and 100), where 0 is
death or the worst health state imaginable and 1
(or 100) represents perfect health or the best pos-
sible health state. Values can be derived through
standard gamble or time trade-off methods, visual
analog scales, or through hybrid psychometrically
based instruments, such as the Quality of Well-
Being Scale (QWB) [15,16], or multiattribute util-
ity theory–based instruments, such as the Health
Utilities Index (HUI) [17,18] or the European
Quality of Life (EQ-5D) index [19]. Like the pre-
vious approaches to HRQL evaluation, health utility/
preference measures are based on at least three (core)
domains of HRQL that are aggregated into a sin-
gle score. Utilities are used to estimate QALYs for
prospective cost-utility or decision-analytic stud-
ies. The increased use of computer-assisted utility
interviews makes the collection of these data dur-
ing clinical trials a viable and potentially cost-
effective option.
 
Respondents.
 
The patient is considered the pri-
mary source of information for HRQL data and is
the preferred respondent (the exception of utility
values is addressed below). There are situations,
however, in which patients are unable to respond
or cannot supply a reliable or valid self-report
(e.g., Alzheimer’s disease, head injury, stroke, or
other cognitive or physical difficulty). In this case,
primary caregivers (close relative or other house-
hold resident who knows the patient well) can be
asked to provide a proxy evaluation. There is evi-
dence that caregivers and family members report
functioning and well-being scores at variance with
patients, especially on measures of psychological
well-being and other less observable domains of
HRQL [20,21]. There is also evidence to suggest
that, when primary caregivers are chosen with
care, these differences can be relatively small, par-
ticularly with respect to physical functioning
[22,23]. Because of the potential for bias, it is im-
portant to maintain a consistent respondent across
treatment groups and throughout the study. If it is
anticipated that patients will deteriorate over
time, it is wise to collect proxy data at the start of
the trial.
Recommendations for the estimation of utilities
and the conduct of cost-effectiveness/cost-utility
analyses are described elsewhere [24]. Briefly,
these values can be estimated from data gathered
from patients during a randomized clinical trial or
from the population in general. To date, few trials
have included utility evaluation, and fewer still
have used standard gamble or time trade-off tech-
niques. Those trials that have estimated utilities
have generally used psychometrically based ques-
tionnaires with society/population-based weight-
ing. The use of population/society-based estimates
is consistent with the recommended standards for
pharmacoeconomic evaluations proposed by Gold
and colleagues [24].
 
Reliability and Validity.
 
The instrument(s) selected
for a trial must be psychometrically sound (i.e., re-
liable and valid). Evidence to this effect should be
documented in the study protocol and appropri-
ately described and cited in any subsequent publi-
cations. The desirable characteristics of a self-
report or survey instrument have been described
by Nunnally and others [25–30]. Table 1 summa-
rizes the characteristics that are critical for mea-
sures used in clinical trials [31].
Tests of reliability (internal consistency, repro-
ducibility) provide evidence of the measurement
error associated with any given instrument. As is
true in any measurement effort, the greater the er-
ror, the more difficult it is to show treatment ef-
fects. Standards from the field of psychometrics
suggest internal consistency reliability coefficients
(Cronbach’s alpha) should be greater than 0.70
for group comparisons, and test-retest reliability
(based on intraclass correlation coefficients) should
be greater than 0.60 in stable patients over a 2-week
interval or less [28]. Reports of clinical trials should
include reliability estimates from the study popu-
lation.
An instrument can be reliable, and yet not
valid. That is, scores may be internally consistent
and stable over time, and yet there is no indication
that the instrument measures what it purports to
measure. Thus, evidence of validity is as impor-
tant, if not more so, than estimates of reliability.
Data concerning an instrument’s validity accrue
over time, as it is used in repeated investigations
by various scientists and in diverse conditions and
settings. Minimally, instruments should demon-
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strate evidence of content and construct validity,
including moderate correlations with instruments
evaluating hypothetically related constructs and/
or with other similar instruments designed to evalu-
ate HRQL. Condition- or disease-specific mea-
sures, for example, should be moderately correlated
with an indicator of disease severity (construct va-
lidity) as well as with generic or other, similar con-
dition-specific measures of HRQL (concurrent va-
lidity). Evidence of discriminant and divergent
validity is desirable but not essential prior to use
within a trial.
Empirical evidence that an instrument is re-
sponsive to change is also desirable but not essen-
tial prior to the onset of a clinical trial. In cases
where this information is not available, the proba-
bility of responsiveness may be inferred from reli-
ability and validity data. In doing so, however, the
investigator(s) must recognize that there is dis-
agreement about whether evidence that an instru-
ment is reliable, correlates with disease indicators,
and can discriminate between clinically meaning-
ful groups at a single point in time (i.e., known
groups validity) necessarily translates into sensi-
tivity to within-group change and between-group
differences with treatment. For studies hypothesiz-
ing improvement in HRQL with treatment, the
primary, and potentially costly, risk is that the in-
strument will not be responsive to treatment ef-
fects and the investigators will be unable to draw
conclusions or proceed with claims. The implica-
tions are more serious in research designs evaluat-
ing HRQL stability with treatment, however. In
these cases, empirical evidence of the instrument’s
sensitivity to change should be well documented.
The instrument(s) selected for a given trial(s)
should be reliable and valid 
 
in the population un-
der investigation.
 
 An instrument developed and
tested in one population is not necessarily valid or
reliable in another. The items and psychometric
properties of a measure for adults, for example,
would not be directly applicable to children. In the
same vein, instruments that work very well in am-
bulatory populations are not necessarily appropri-
ate for inpatient use. For international trials, there
should be evidence of reliability and validity of the
instrument in each of the populations under study.
Guidelines for the linguistic translation and cul-
 
Table 1
 
Critical characteristics for HRQL evaluation in clinical trials
 
Validity General: Does the instrument measure what it is intended/designed to measure?
Trial specific: Is the measure appropriate for the patients, setting, and intervention under investigation?
Content validity Does the instrument measure HRQL as generally defined? Are there scale scores to represent the physical,
functional, psychological, and social domains?
Does the instrument reflect the aspects of HRQL important to the patients themselves?
Are the key dimensions expected to change with therapy adequately represented?
Construct validity Does the instrument behave in a manner consistent with the underlying construct of HRQL? For example, does
it correlate with other instruments designed to measure constructs related to HRQL? Does it differentiate
groups known to differ in HRQL? Evidence of construct validity is accumulated over time.
Reliability To what extent is error present in the instrument?
Internal consistency To what extent is there consistency within the instrument itself? Across items within domains, across all items
in the scale? These estimates appear as Cronbach’s coefficient alpha (
 

 
) or the Kuder-Richardson (KR-20) and
reflect the covariation among the items within a scale.
Reproducibility To what extent is the instrument stable over time? These estimates are expressed as intraclass and Pearson
correlation coefficients.
Responsiveness To what extent does the instrument detect change over time with alterations in disease state and in response to
treatment?
Interpretability What is the scaling structure of the instrument? How are scores interpreted?
What do changes represent? To the patient? To the provider? Clinically meaningful change or minimal-important
difference refers to the magnitude of change in HRQL that would induce a change in patient management [69].
Respondent burden What is the time and effort required to complete an instrument?
Translation For instruments developed in one country and considered for use in another or for cross-national trials:
Has the measure been linguistically and culturally translated?
Have these translated versions been psychometrically validated?
 
Source: Leidy et al. [31]. Reprinted with permission.
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tural adaptation of HRQL measures are available
[32–35]. Because evidence of reliability and valid-
ity of the culturally adapted HRQL instrument is
a necessary requirement for pooling of data across
different clinical centers from different countries
participating in an international trial, the quality
of the linguistic translation and the validity of the
cultural adaptation need to be evaluated before use.
In situations in which reliability and validity ev-
idence is sparse or nonexistent (as is often the case
in condition-specific instruments, particularly for
relatively rare diseases or unusual situations and
in the situations outlined above), pretrial validation
studies are necessary to assure that the instrument
is reliable, valid, and responsive in the conditions
set forth by the trial itself. Although psychometric
data from one population provide useful back-
ground information and preliminary evidence that
a measure is sound, these data cannot be general-
ized to another population. Reliability and validity
estimates for an instrument developed and tested in
Canada or the United Kingdom, for example, may
suggest it is useful in the United States; however,
further evaluation must be performed to deter-
mine if the characteristics do, in fact, hold [35,36].
Similarly, a pulmonary-specific instrument tested
in adults with emphysema and chronic bronchitis
requires further validation before it can be applied
to patients with asthma.
In the event a psychometrically sound instru-
ment is not available, a new instrument must be
developed, either through adaptation of an exist-
ing measure or item-by-item construction. Instru-
ment development often requires 1 to 2 years of
effort (or more, particularly for multinational
studies), including pilot tests and studies to evaluate
the measure’s reliability, validity, and responsive-
ness. A carefully constructed instrument, based on
the literature and structured or unstructured pa-
tient interviews and subjected to clinical content
review, may require only one well-designed and
well-executed validation study to demonstrate the
instrument’s usefulness as an HRQL indicator.
Measures that fail the initial testing (e.g., reliabil-
ity estimates less than 0.60 and/or failed valida-
tion tests) will require further developmental and
empirical work. Whether an instrument is widely
used and well published or relatively new, the
same standards of reliability and validity hold
[25–27,29]. If the intent is to pursue a HRQL
claim for labeling and promotion, reliability and
validity should be established prior to the trial(s)
through which such claims are to be substanti-
ated. It is both acceptable and wise to perform
these tests during Phase II studies or parallel, ex-
ploratory trials. HRQL data from clinical trials in
which untested instruments are used (i.e., for
which there is no a priori evidence of reliability
and validity) are not valid.
 
Mode or Method of Administration.
 
Because the
reliability and validity of an instrument may
change with administration methods, an instru-
ment developed and tested using one mode of ad-
ministration (e.g., self-administered questionnaire)
should be validated for use in another mode (e.g.,
telephone interview administration) prior to its
application in a clinical trial [37]. Investigators
should avoid mixing modes of administration
within a clinical trial, particularly when there is
evidence of score differences. If different modes of
administration are required, they should be stan-
dardized across patients and treatment groups
(e.g., self-completed administration at baseline,
with follow-up assessments by telephone inter-
view).
 
Subject Burden.
 
The selection of an instrument
for any given trial involves a trade-off between the
burden of administration and the breadth and
depth of the data [38]. Burden indicators include
the number of items or questionnaires a patient is
asked to complete and the complexity and time re-
quired to complete the task, within the context of
patient capabilities. Clinician time and the ex-
pense associated with gathering and analyzing
data are also considerations. Longer instruments
are generally more comprehensive, but can be bur-
densome; shorter instruments tend to have more
error and are often less comprehensive. A number
of instruments, such as the SF-36 [10] and Quality
of Life in Epilepsy Inventory-89 (QOLIE-89) are
available in both a long and short form [39,40].
Shorter instruments can be appropriate if (1) evi-
dence of multidimensionality, reliability, and va-
lidity is sound, or (2) the data will not be used for
labeling or promotional claims, but rather are in-
tended for exploratory analyses and/or scientific
exchange only.
In summary, there are multiple approaches and
instruments for measuring HRQL. The selection
of the best approach for any given trial requires a
careful review of the relevant domains of HRQL,
the instruments that can assess these domains in
the relevant study population, and the evidence of
the instrument’s psychometric characteristics. It is
likely that this review will yield several viable
measurement options. The study protocol and fi-
nal report should include rationale for the instru-
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ment(s) ultimately selected and a summary of the
evidence regarding the measure’s psychometric
properties with respect to the target population.
 
Statistical Analysis
 
There are a number of analytical issues specific to
HRQL evaluation in clinical trials, including sta-
tistical power, the analysis of multiple related end-
points, handling missing data, and longitudinal
data structure. The combination of multiple re-
lated HRQL endpoints collected over time in a
group of clinical trial subjects with some level of
missing observations further complicates the anal-
ysis of HRQL data.
 
Statistical Power.
 
To support an HRQL claim, the
study must be powered adequately to detect statis-
tically significant HRQL change, within and be-
tween treatment groups. By convention, statistical
power of 80% to 90% is considered adequate,
given assumptions about 
 
p
 
 values, endpoint vari-
ance, and clinically meaningful effect sizes. Ratio-
nale and supporting power calculations should be
documented in the study protocol.
 
Multiple Related Endpoints.
 
Because HRQL instru-
ments involve multiple, interrelated domains and
subscales, issues associated with the statistical
analysis of multiple interrelated endpoints apply.
In situations in which the primary HRQL end-
point is overall quality of life, it is possible to use
an aggregate score that summarizes effects across
the multiple domains. A variety of methods can be
used to construct aggregate scores. The SF-36
Health Survey, for example, uses factor weights to
construct two summary scores: one more heavily
weighted along the physical domains (the physical
component summary [PCS] score), the other more
heavily weighted along the mental health domains
(the mental component summary [MCS] score)
[39,41]. Mental and physical health summary
scores are also available for the condition-specific
MOS HIV Health Survey [42]. Some HRQL ques-
tionnaires, such as the EORTC QLQ-C30 [43]
and the MOS HIV Health Survey [44] ask about
overall health/global quality of life as a separate
domain and present the results as a separate score.
These scores can provide insight into patient per-
ception of overall quality of life, but are insuffi-
cient to substantiate a HRQL claim when used in
isolation or as a primary endpoint. Utility mea-
sures, such the HUI and EQ-5D, use a variety of
methods to aggregate data across domains in or-
 
der to arrive at the single score necessary to per-
form cost-utility analyses.
Although aggregate scores are useful for simpli-
fying data analyses, they can also magnify or mask
treatment differences [41]. Aggregating across in-
dividual items places greater weight on scales with
more items; factor score weights assign differential
weighting based on sample-specific data; and
computing a mean across subscale or domain
scores treats all scales equally. Each scoring algo-
rithm can lead to different outcomes. For exam-
ple, if 70% of the items comprising a three-
domain instrument address symptoms, and the to-
tal score is computed by taking the mean across all
items, then the symptom domain would carry
more weight. A symptom-targeted intervention is
more likely to show HRQL effects under this scor-
ing algorithm than under an algorithm in which
the three domains are treated equally. Investiga-
tors should use the scoring algorithm specified by
the instrument developers, unless a case can be
made for reducing bias through an alternative
scoring approach. The method for aggregating
scores should be specified a priori in the statistical
analysis plan.
Comparison of multiple related endpoints can be
accomplished by conducting multiple univariate
analysis of variance (ANOVA) models (i.e., a
model for each endpoint) with adjustment for mul-
tiple comparisons, multivariate analysis of vari-
ance, growth curve analysis, or global test statistics.
Univariate ANOVA models with corrections for
multiple comparisons conserve the absolute overall
error rate resulting in overly conservative tests and
inflated Type II error [45]. A number of alternative
analytic techniques have been identified for evalu-
ating multiple endpoints in clinical trials [46–48].
Multivariate test statistics, such as Hotelling’s T
 
2
 
,
can be used to test for any overall deviations from
the null hypothesis but may not have sufficient
power to detect treatment-related differences.
Growth curve analysis [49] can also be used to
compare multiple endpoints, measured over time.
Global test statistics and closed test procedures
[46,50] have been proposed as an approach to
preserving experiment-wise error rates. Statisti-
cally significant global tests, suggesting treatment-
related differences, are followed by pair-wise tests
of each HRQL endpoint to determine the source
of these differences. A simpler approach involves
the specification of primary and secondary end-
points. A limited number of primary endpoints are
identified and serve as the main focus of the analy-
ses. Results of the secondary endpoints facilitate
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interpretation and the generation of hypotheses
for further study. This approach limits the multi-
ple comparison problem and forces investigators
to identify a priori the main treatment effects on
HRQL. It is important to note, however, that in
the United States, the FDA, to date, has not per-
mitted the use of results from secondary endpoint
analyses as the basis for product promotion. If a
comprehensive HRQL marketing campaign is de-
sired, trials should be designed accordingly.
 
Handling Missing Data.
 
Missing HRQL obser-
vations can be a significant problem in clinical trials
[51–53]. Like clinical data, missing HRQL data
occur because of mortality, disease progression,
treatment-related adverse effects, and reasons un-
related to treatment or the underlying disease (e.g.,
poor implementation of research protocol). Tech-
nically, missing data that can be classified as com-
pletely random [54] can be ignored with no seri-
ous bias introduced into the statistical analysis.
Unfortunately, there are few situations in which
such classification can be made with complete
confidence. In fact, there is substantial evidence to
suggest that missing HRQL data are often related
to either the treatment or the underlying disease.
In clinical trials of antineoplastic or antiretroviral
therapies, for example, several researchers have
found that baseline health status scores are associ-
ated with mortality, disease progression, and study
discontinuation [55–59].
There are several approaches for handling missing
HRQL data in clinical trials, with no consensus on a
single best method [52,53]. The traditional intent-to-
treat and last observation carried forward (LOCF)
approach works reasonably well if there are rela-
tively few missing observations and the frequency of
missing data is comparable across treatment groups.
With larger proportions or differential rates of miss-
ing data, LOCF techniques can underestimate the
impact of treatment on HRQL. The extent of bias is
proportional to differences in mean HRQL scores
between study completers and noncompleters and to
the proportion of noncompleters. For example,
Testa et al. [60] found no differences in HRQL be-
tween nifedipine gastrointestinal therapeutic system
(GITS) and atenolol treated hypertensive patients
over 24 weeks using LOCF for all patients. How-
ever, when completers in each group were com-
pared, statistically significant treatment differences
were observed. Differential rates of missing HRQL
data across treatment groups are likely to influence
statistical analysis of HRQL endpoints in unknown
ways.
Heyting et al. [61], Lavori et al. [62], and oth-
ers examined methods derived from surveys and
observational studies with nonresponse, including
multiple imputation techniques. Although the
methods appear useful, they have not been applied
to clinical trials. In a simulation analysis, Revicki
et al. [63] found that an empirical Bayes technique
for imputing missing values approximates treat-
ment group means and slopes (representing rates
of change over time), even with up to 30% missing
data due to mortality, while the LOCF approach
consistently underestimates treatment effects. Re-
search on the optimal methods for handling miss-
ing data is ongoing.
Methods for handling missing data should be
identified and described in the statistical analysis
plan. At minimum, LOCF approaches in addition
to one or more of the newer techniques for imput-
ing missing data should be used. If the sample size
is sufficient, a comparison of completers versus
noncompleters within and across treatment groups
should be performed to assess the sensitivity of the
results to discontinuation. If the results of the be-
tween-treatment comparisons are consistent across
the different approaches, then there can be more
confidence in the study results.
 
Longitudinal Data Structure.
 
Most clinical trials
use a longitudinal data structure, that is, repeated
within-subject measurement over a specified pe-
riod of time (e.g., 24 weeks). As is true of any re-
peated measures analyses, these HRQL observa-
tions are not independent. Failure to consider the
autocorrelation structure in the statistical analysis
may result in bias in estimating the test statistics
[64,65]. Repeated measures analysis using mixed-
model analysis of variance [66,67] and longitudi-
nal random-effect models [68] have been recom-
mended for analyzing treatment differences in
HRQL [45]. Mixed-model ANOVA can incorpo-
rate noninformative missing data and allow com-
parisons of treatment by time interactions. Univari-
ate analysis of covariance models of LOCF HRQL
endpoint data may not capture the richness of the
longitudinal data collected in long-term clinical
trials.
In summary, the statistical analysis plan for
HRQL data must be specified during protocol de-
velopment and completed prior to the data analy-
sis phase of the study. This plan should clearly
and specifically describe the rationale for and how
multiple HRQL endpoints will be combined into
summary measures, specify primary and second-
ary endpoints, outline the methods for handling
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missing data, and describe the hypothesis testing
procedures and any adjustment or handling of
multiple statistical comparisons. The latter should
include the analytical procedures to be used in
handling the longitudinal structure of the HRQL
data (if more than a baseline and a single follow-
up endpoint assessment are included).
 
Interpretation
 
Statistical Significance.
 
It is generally easier to
detect treatment effects and demonstrate product
superiority in placebo-controlled trials than in
studies comparing two or more active treatments.
This is true for both clinical effectiveness and
HRQL outcomes. There are situations in which
the HRQL hypotheses may be one of equivalence
rather than superiority. Desirable properties of an-
tihypertensives, antineoplastics, and antiretrovi-
rals are to minimize the adverse impact of treat-
ment on HRQL, while still affecting the targeted
disease indication. In this case, lack of statistical
significance (i.e., failure to show a difference be-
tween active treatment and placebo or no within-
treatment change observed over time) can demon-
strate that a product does no harm, provided that
the study is appropriately powered. (Purposefully
underpowering a study to demonstrate equiva-
lence is unacceptable, and unethical.) Equivalence
in HRQL outcomes may also be hypothesized in
trials involving two or more active treatment
arms. If treatment-group differences in HRQL are
expected, the domains in which the treatment op-
tions are most likely to differ can be selected as
primary HRQL endpoints, with the understanding
that in some countries it may not be possible to
use the secondary endpoints in product marketing.
Hypotheses of equivalence or superiority and pri-
mary and secondary HRQL endpoints must al-
ways be specified a priori in the study protocol.
The standard probability rule of 0.05 or 0.01 is
generally used as the criterion for rejecting the null
hypothesis of no HRQL effect within and/or be-
tween groups, with adjustments made for multiple
comparisons. There are situations, however, in
which an alternative, less stringent probability
level may be considered reasonable and appropri-
ate. A high-risk study involving a relatively small
sample of patients with end-stage renal failure, for
example, may be powered for a clinical outcome.
The instrument selected to evaluate HRQL, a sec-
ondary but important outcome of the study, has
strong evidence to support a clinically meaningful
change score (see the next section). However, this
score would fail to achieve statistical significance
under the traditional probability rule. In other
words, the study is underpowered for HRQL at
the 0.05 level, although a clinically meaningful
change (discussed in the next section) could be
demonstrated at a probability level of less than,
for example, 0.10. In this case, a larger 
 
p
 
 level
(e.g., 0.10) for the HRQL component of the study
is justified. It is likely that scenarios such as these,
involving high-risk, high-need patients or patients
with relatively rare disorders, will become more
commonplace, suggesting that the acceptable prob-
ability level should be considered on a case by case
basis during the development of the study proto-
col. The probability level for HRQL outcomes
must be selected and justified a priori and in-
cluded in the study protocol; post hoc rationaliza-
tion is not acceptable.
 
Clinical Significance.
 
An important question in
HRQL research is the extent to which a given
change in HRQL score is clinically significant. The
extent to which change is perceptible and mean-
ingful will depend on the interpreter. Changes that
are important to patients, for example, may or
may not be perceptible or significant to the clini-
cian. Similarly, patients and/or clinicians may feel
that the HRQL changes are important, but must
be disregarded in the short term in light of the
health risks involved in altering treatment. Every
effort should be made to interpret results in terms
that are meaningful to the patients themselves. A
treatment can lead to a statistically significant im-
provement in HRQL, and yet patients or clinicians
do not consider the change substantive.
The determination of a clinically meaningful
change score (also referred to as a minimal impor-
tant difference) is a relatively recent pursuit by
HRQL scientists, and, as such, the field is in its in-
fancy [69,70]. Progress is being made, however,
and several instruments are now available with
empirically based guidelines for interpreting out-
comes in terms of clinical significance. Developers
of the generic SF-36, for example, suggest that a 5
to 10 point change (0–100 scale) along any of the
instrument’s eight subscales is clinically meaningful
[10]. Similarly, in the EORTC QLQ-C30, changes
of 5 to 10 scores (0–100 scale) are perceptible to
patients [70] and may reflect real changes in dis-
ease [71]. Developers of the condition-specific
Asthma Quality of Life (AQLQ) index propose
that a 0.5 change (1–7 scale) along any of the four
subscales represents a minimal important differ-
ence [72].
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Despite advances in the formulation of guide-
lines for interpreting change scores in HRQL re-
search, many unanswered questions remain. Is it
reasonable, for example, to expect that a clinically
meaningful change score would be the same
across levels of disease severity or, in the case of a
generic instrument, across disease groups? Does a
0.5 change (on a 7-point scale) carry the same
meaning at the top and the bottom of the scale
(e.g., for a mild and severe asthmatic)? Is a 5-point
change in the HRQL of an older woman with dia-
betes interpreted in the same way as a 5-point
change in the HRQL of a young man with hyper-
tension? For purposes of clinical trial design and
evaluation for quality of life claims, appropriate
scientific justification should be demonstrated for
interpreting study results in terms of clinically
meaningful change.
 
Aggregating Evidence
 
How many and what types of studies are required
to substantiate an HRQL claim for labeling or pro-
motion? The key issue here is confirmatory evi-
dence. The current historical record of FDA ap-
proved labeling in the United States is inconsistent,
at times requiring only a single study with no con-
trol group [73] or one well-designed randomized
controlled clinical trial with HRQL as the primary
endpoint [74]. Evidence required for claiming
HRQL effects should be consistent with the stan-
dards to which other clinical claims are held. In
the United States, changes in evidentiary require-
ments for clinical effectiveness claims with the
FDA Modernization Act of 1997 should also ap-
ply to HRQL.
We suggest that, in general, two well-designed
randomized clinical trials with unequivocal results
should provide sufficient evidence of an HRQL ef-
fect to substantiate a claim in a given population.
Multiple clinical trials are required when HRQL is
considered a secondary endpoint or is not well in-
tegrated into the study design, or in situations in
which the results are equivocal. Although the
same HRQL measure is recommended when more
than one clinical trial is conducted, consistent re-
sults across studies using different but appropriate
and psychometrically sound measures should be
permissible. At no time is it acceptable (in fact, it
is unethical) to misrepresent the effectiveness of
treatment through selective reporting of HRQL
results, either by addressing only one or two of the
domains assessed or by failing to report negative
HRQL effects within or across studies.
We also suggest that results from a single well-
designed multicenter, randomized controlled clini-
cal trial where HRQL is a primary endpoint and
the study is well executed (including a retention
rate exceeding 90% in each treatment group and
statistical power of at least 80%), together with
supportive confirmatory evidence, be considered
sufficient evidence for an HRQL claim. This is
consistent with Sections 115a and 205 of the FDA
Modernization Act of 1997 clarifying the number
of clinical investigations required for approval in
the United States [75,76].
 
Future Trends
 
The future of health status assessment in clinical
trials will likely be influenced by item response
theory–based instruments, and computer adaptive
testing designed to measure specific domains of
HRQL [77,78]. Briefly, item response theory
serves as the foundation for the construction of in-
struments tailored to individual patients, while
computerized adaptive testing provides the survey
technique for obtaining responses from individual
respondents. Pools of items tapping different
HRQL domains (i.e., physical functioning, emo-
tional well-being) are constructed and the mea-
surement characteristics of individual items and
the relationships between items are evaluated. The
resulting pool of items can be used to assess func-
tioning along the broad continuum of a specific
domain. For example, they can characterize the
physical functioning of persons who are superior
athletes as well as persons who are confined to
bed or home. Different patients are administered
different sets of four to five items from the total
item bank tailored to their level of functioning and
well-being; meaningful scores are constructed for
all patients along each HRQL domain. Item re-
sponse theory–based instruments and computer
adaptive testing allow very precise and efficient
measurement of generic domains of HRQL. Al-
though theoretically possible, extensive construc-
tion and testing of item banks within different
HRQL domains are required before this approach
can be used in clinical trials [77,78].
Computer-assisted and computer-administered
data collections are becoming accepted and desir-
able approaches for gathering HRQL data in de-
scriptive studies and clinical trails. Computer-
administered instruments are not only acceptable
to patients [79,80], but can yield very high-quality
data. There are a number of challenges related to
the acceptance of electronically collected data for
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HRQL claims, all of which are surmountable. The
first is the assurance of data integrity (i.e., the de-
velopment of procedures for ensuring that elec-
tronic data are, in fact, the responses of patients
themselves [or proxy, if appropriate] and that the
methods for collecting and transmitting the data
are tamper-proof). Second, there are relatively few
published studies on the comparability of com-
puter-administered, self-administered, and inter-
viewer-administered HRQL instruments, making
it difficult to synthesize information across studies,
or in select circumstances, using multiple methods
within a given study. Finally, some patients who
are otherwise eligible for a clinical trial may be un-
able to complete computer-administered HRQL in-
struments. This requires a change in the sample se-
lection criteria, which could bias the study, or the
use of mixed methods for data collection, which is
ill advised unless the comparability of data across
methods is known. It is reasonable to expect that
computer-administered instruments in HRQL out-
comes trials will not only be acceptable but com-
monplace as the issues of data integrity and com-
parability are resolved.
 
Summary
 
As the evaluation of HRQL endpoints in drug and
device development continues to grow, interest in
using these outcomes for labeling and promo-
tional purposes increases. It is vital that these
claims be based upon sound scientific evidence.
There is consensus in the HRQL scientific commu-
nity on the minimum domains that must be as-
sessed in order to consider the outcome HRQL
(i.e., physical, psychological, and social function
and well-being). There is also consensus on what
constitutes sound scientific HRQL research. The
challenge facing industry, national regulatory agen-
cies such as the FDA, and the scientific community
is to reach consensus on the criteria for evaluating
the scientific validity of data that will ultimately
be used for labeling and promotion. This paper
proposes the minimum criteria for designing and
implementing studies that will be used for these
purposes. The protocol should include well-docu-
mented rationale for the domains of HRQL to be
assessed and the instruments selected, and a thor-
ough presentation of the instrument’s psychomet-
ric characteristics. It should also describe methods
for clinic staff training to optimize data quality,
and include a data analysis plan, developed a pri-
ori, that outlines the methods to be used for han-
dling missing data, multiple related endpoints, and
longitudinal data structure. Finally, the protocol
should specify the criteria for interpreting results
in terms of statistical and clinical significance.
Clearly, technologic and scientific advances will
bring new methods for gathering and analyzing
HRQL data. The acceptability of these methods
for clinical trials and claims should be based on
the empirical evidence of their reliability and va-
lidity.
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